ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Ascendis Pharma A/S

Tuborg Boulevard 12
Hellerup 2900
Denmark
45 70 22 22 44
http://www.ascendispharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees216

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael Wolff JensenChairman, Sr. VP & Chief Legal OfficerN/AN/A1971
Mr. Jan Møller MikkelsenPres, CEO, Member of Exec. Board & Exec. DirectorN/AN/A1960
Mr. Scott T. SmithCFO, Sr. VP & Member of Exec. BoardN/AN/A1974
Mr. Peter RasmussenVP of Fin. & Principal Accounting OfficerN/AN/A1969
Ms. Lotte SønderbjergChief Admin. Officer & Sr. VPN/AN/A1961
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone has completed Phase I clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

Corporate Governance

Ascendis Pharma A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.